Press releases appear below, filter by date.
Chiesi has been publicly reprimanded for providing inaccurate information to the PMCPA during the course of a complaint about a leave piece and again during the course of a subsequent audit and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Chiesi Limited, Eli Lilly and Company Limited and Bayer Healthcare have each breached Clause 2 of the ABPI Code of Practice. Bayer Schering Pharma has been publicly reprimanded.
Chiesi Ltd and Vifor Pharma UK Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, Chiesi was publicly reprimanded.
Proposals to amend the Code agreed at ABPI General Meeting on 20 November.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry and the PMCPA Constitution and Procedure were agreed at the Half Yearly General Meeting of the ABPI on 20 November 2014.
The consultation has now closed.
Consultation launched on proposed changes to the ABPI Code of Practice for the Pharmaceutical Industry and the Constitution and Procedure for the Prescription Medicines Code of Practice Authority